The science is advancing faster than the ethics can keep up. Who decides what gets edited? Who has access? And where exactly is the line between curing disease and designing people?
CRISPR can edit embryos — and that changes everything
There are two fundamentally different ways CRISPR can be used on humans. The first is somatic gene editing: editing the cells of a living person. Changes made this way affect only that individual and cannot be inherited. This is the basis of Casgevy and virtually every other CRISPR therapy currently in clinical trials, and it has achieved broad acceptance among scientists and ethicists.
The second is germline editing: editing the DNA of an embryo, egg, sperm, or early-stage embryo. Changes made here are inherited — they pass to every cell in the resulting person, and potentially to their children and grandchildren. This type of editing crossed from theory to reality in 2018 when Chinese scientist He Jiankui announced the birth of twin girls whose embryos he had edited with CRISPR without proper consent or oversight. The international scientific community responded with near-universal condemnation. He was later imprisoned.
⚠️ The He Jiankui case: He Jiankui used CRISPR to edit the CCR5 gene in human embryos to confer HIV resistance, resulting in the birth of twin girls and a third child. He lacked adequate safety data, bypassed ethical oversight, and falsified documents. The case triggered global calls for a moratorium on heritable human genome editing.
The designer baby problem
The ethical concern that generates the most public alarm is the possibility of using CRISPR not to cure disease but to enhance traits — choosing a child’s intelligence, appearance, athletic ability, or disease resistance before they are born. This is what the term ‘designer babies’ refers to, and while it remains beyond current scientific capabilities (most complex traits involve thousands of genes with unpredictable interactions), the direction of the technology makes it a question that has to be addressed now.
The core ethical tension is this: if CRISPR can eliminate a gene that causes a painful, life-shortening condition, most people would consider that medicine. But what about a gene variant associated with slightly reduced cognitive performance? Or one linked to a marginally increased risk of a common disease? The line between treatment and enhancement is not sharp — and where you draw it depends on values, not just science.
Who gets access — and who doesn’t?
Even setting aside the germline debate, access is one of the most pressing real-world ethical issues facing CRISPR medicine right now. Casgevy, the approved sickle cell therapy, is among the most expensive treatments ever developed — priced at approximately $2.2 million per patient in the United States. The disease it treats disproportionately affects people of African descent, many of whom live in countries with healthcare systems that could never afford this treatment.
This creates a troubling dynamic: a technology funded in part by public research dollars, targeting a disease that devastates disadvantaged populations, priced in a way that makes it inaccessible to most of the people who need it most. The science has succeeded. The economics haven’t caught up.
Off-target effects: the technical safety question
Beyond the philosophical debates, there are concrete technical concerns about CRISPR’s safety. Off-target effects occur when the guide RNA directs Cas9 to cut at a location other than the intended target — potentially disrupting a gene that was functioning correctly, or even activating a cancer-causing gene. On-target effects can also cause problems when the cell’s repair process doesn’t proceed as intended.
The newer CRISPR tools — base editors, prime editors, epigenome editors — significantly reduce these risks compared to standard Cas9 cutting. But they don’t eliminate them. Every clinical trial currently includes extensive genomic sequencing of edited cells to screen for off-target events. As of 2025, no approved CRISPR therapy has produced clinically significant off-target effects in patients — but long-term safety monitoring is still ongoing for all treated individuals.
🔬 Current consensus: As of 2025, approximately 250 CRISPR clinical trials are registered globally, with over 150 active. The scientific community broadly supports somatic (non-heritable) CRISPR therapy for disease. There is near-universal consensus that heritable germline editing in humans should not proceed until safety and ethical frameworks are established.